Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 16/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872492 | 0.90 | TTK (0.44) | TTK | |
| SCHEMBL3720438 | 0.88 | TTK (0.50) | TTK | |
| SCHEMBL123799 | 0.87 | TTK (0.51) | TTK | |
| SCHEMBL3720474 | 0.86 | TTK (0.48) | TTKRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL3723006 | 0.85 | TTK (0.50) | TTK | |
| SCHEMBL16872495 | 0.83 | TTK (0.46) | TTK | |
| SCHEMBL16872497 | 0.82 | TTK (0.44) | TTK | |
| SCHEMBL3719521 | 0.80 | TTK (0.56) | TTK | |
| SCHEMBL119744 | 0.80 | TTK (0.58) | TTK | |
| SCHEMBL3725695 | 0.78 | TTK (0.50) | TTKRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | claimed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | claimed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | claimed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | TTBK1, TTK, TTBK2 | TTK 2/4885RAB9A 2605/4885NPC1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.